278 related articles for article (PubMed ID: 25951927)
1. Release of 5-Aminosalicylic Acid (5-ASA) from Mesalamine Formulations at Various pH Levels.
Abinusawa A; Tenjarla S
Adv Ther; 2015 May; 32(5):477-84. PubMed ID: 25951927
[TBL] [Abstract][Full Text] [Related]
2. Dissolution of Commercially Available Mesalamine Formulations at Various pH Levels.
Tenjarla S
Drugs R D; 2015 Jun; 15(2):211-5. PubMed ID: 26115756
[TBL] [Abstract][Full Text] [Related]
3. In vitro biorelevant models for evaluating modified release mesalamine products to forecast the effect of formulation and meal intake on drug release.
Andreas CJ; Chen YC; Markopoulos C; Reppas C; Dressman J
Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):39-50. PubMed ID: 26391972
[TBL] [Abstract][Full Text] [Related]
4. Gastrointestinal release behaviour of modified-release drug products: dynamic dissolution testing of mesalazine formulations.
Goyanes A; Hatton GB; Merchant HA; Basit AW
Int J Pharm; 2015 Apr; 484(1-2):103-8. PubMed ID: 25721685
[TBL] [Abstract][Full Text] [Related]
5. 5-Aminosalicylic acid containing drugs. Delivery, fate, and possible clinical implications in man.
Christensen LA
Dan Med Bull; 2000 Feb; 47(1):20-41. PubMed ID: 10709142
[TBL] [Abstract][Full Text] [Related]
6. Mucosal 5-aminosalicylic acid concentration, drug formulation and mucosal microbiome in patients with quiescent ulcerative colitis.
Olaisen M; Spigset O; Flatberg A; Granlund AVB; Brede WR; Albrektsen G; Røyset ES; Gilde B; Sandvik AK; Martinsen TC; Fossmark R
Aliment Pharmacol Ther; 2019 May; 49(10):1301-1313. PubMed ID: 30895635
[TBL] [Abstract][Full Text] [Related]
7. Concentration dependence of 5-aminosalicylic acid pharmacological actions in intestinal mucosa after oral administration of a pH-dependent formulation.
Hirayama M; Toda R; Ozaki T; Hasegawa J; Nakamura T; Naraki Y; Haraguchi Y; Hori Y; Tanaka T; Takei M; Mera Y; Yoshii K; Kawabata Y
Mol Pharm; 2011 Aug; 8(4):1083-9. PubMed ID: 21553927
[TBL] [Abstract][Full Text] [Related]
8. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Feagan BG; Macdonald JK
Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
[TBL] [Abstract][Full Text] [Related]
9. 5-ASA colonic mucosal concentrations resulting from different pharmaceutical formulations in ulcerative colitis.
D'Incà R; Paccagnella M; Cardin R; Pathak S; Baldo V; Giron MC; Sturniolo GC
World J Gastroenterol; 2013 Sep; 19(34):5665-70. PubMed ID: 24039359
[TBL] [Abstract][Full Text] [Related]
10. Influence of Pharmaceutical Formulation on the Mucosal Concentration of 5-Aminosalicylic Acid and N-Acetylmesalamine in Japanese Patients with Ulcerative Colitis.
Yamamoto Y; Masuda S; Nakase H; Matsuura M; Maruyama S; Hisamatsu T; Suzuki Y; Matsubara K
Biol Pharm Bull; 2019 Jan; 42(1):81-86. PubMed ID: 30369547
[TBL] [Abstract][Full Text] [Related]
11. Measurement of in vivo Gastrointestinal Release and Dissolution of Three Locally Acting Mesalamine Formulations in Regions of the Human Gastrointestinal Tract.
Yu A; Baker JR; Fioritto AF; Wang Y; Luo R; Li S; Wen B; Bly M; Tsume Y; Koenigsknecht MJ; Zhang X; Lionberger R; Amidon GL; Hasler WL; Sun D
Mol Pharm; 2017 Feb; 14(2):345-358. PubMed ID: 28009518
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of ulcerative colitis treatment in Germany: a comparison of two oral formulations of mesalazine.
Prenzler A; Yen L; Mittendorf T; von der Schulenburg JM
BMC Health Serv Res; 2011 Jul; 11():157. PubMed ID: 21729262
[TBL] [Abstract][Full Text] [Related]
13. A dynamic model of colonic concentrations of delayed-release 5-aminosalicylic acid (Asacol).
Thorpe MP; Ehrenpreis ED; Putt KS; Hannon B
Aliment Pharmacol Ther; 2009 Jun; 29(11):1193-201. PubMed ID: 19222409
[TBL] [Abstract][Full Text] [Related]
14. Simulated comparison of topical and oral formulations of 5-aminosalicylate for the treatment of ulcerative colitis.
Stobaugh DJ; Deepak P; Thorpe M; Hannon B; Ehrenpreis ED
Inflamm Bowel Dis; 2013 Feb; 19(2):301-8. PubMed ID: 22644716
[TBL] [Abstract][Full Text] [Related]
15. Review article: 5-aminosalicylate formulations for the treatment of ulcerative colitis--methods of comparing release rates and delivery of 5-aminosalicylate to the colonic mucosa.
Lichtenstein GR; Kamm MA
Aliment Pharmacol Ther; 2008 Sep; 28(6):663-73. PubMed ID: 18532992
[TBL] [Abstract][Full Text] [Related]
16. Oral 5-ASA therapy in ulcerative colitis: what are the implications of the new formulations?
Sandborn WJ
J Clin Gastroenterol; 2008 Apr; 42(4):338-44. PubMed ID: 18277908
[TBL] [Abstract][Full Text] [Related]
17. Encapsulated mesalamine granules (Apriso) for ulcerative colitis.
Med Lett Drugs Ther; 2009 May; 51(1312):38-9. PubMed ID: 19448588
[TBL] [Abstract][Full Text] [Related]
18. Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis: comparison of orally administered mesalamine and sulfasalazine.
Naganuma M; Iwao Y; Ogata H; Inoue N; Funakoshi S; Yamamoto S; Nakamura Y; Ishii H; Hibi T
Inflamm Bowel Dis; 2001 Aug; 7(3):221-5. PubMed ID: 11515848
[TBL] [Abstract][Full Text] [Related]
19. Dissolution profiles of mesalazine formulations in vitro.
Stolk LM; Rietbroek R; Wiltink EH; Tukker JJ
Pharm Weekbl Sci; 1990 Oct; 12(5):200-4. PubMed ID: 2255590
[TBL] [Abstract][Full Text] [Related]
20. The study of marketed and experimental formulation approaches enabling site-specific delivery of mesalamine in patients with inflammatory bowel disease.
Kadiyala I; Jacobs D
Recent Pat Drug Deliv Formul; 2014 Apr; 8(1):3-11. PubMed ID: 24111938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
